# Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema

> **NCT00262288** · PHASE2,PHASE3 · COMPLETED · sponsor: **Pharming Technologies B.V.** · enrollment: 14 (actual)

## Conditions studied

- Genetic Disorders

## Interventions

- **DRUG:** i.v. recombinant human C1 inhibitor

## Key facts

- **NCT ID:** NCT00262288
- **Lead sponsor:** Pharming Technologies B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2007-01
- **Final completion:** 2007-01
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2013-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00262288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00262288, "Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT00262288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*